<code id='212D0C23DB'></code><style id='212D0C23DB'></style>
    • <acronym id='212D0C23DB'></acronym>
      <center id='212D0C23DB'><center id='212D0C23DB'><tfoot id='212D0C23DB'></tfoot></center><abbr id='212D0C23DB'><dir id='212D0C23DB'><tfoot id='212D0C23DB'></tfoot><noframes id='212D0C23DB'>

    • <optgroup id='212D0C23DB'><strike id='212D0C23DB'><sup id='212D0C23DB'></sup></strike><code id='212D0C23DB'></code></optgroup>
        1. <b id='212D0C23DB'><label id='212D0C23DB'><select id='212D0C23DB'><dt id='212D0C23DB'><span id='212D0C23DB'></span></dt></select></label></b><u id='212D0C23DB'></u>
          <i id='212D0C23DB'><strike id='212D0C23DB'><tt id='212D0C23DB'><pre id='212D0C23DB'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:54274
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Why Novartis is changing the name of its research labs
          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas